Google parent Alphabet Inc and French drugmaker Sanofi plan to invest about US$500 million in a joint venture to tackle diabetes amid forecasts for the number of people with the disease to surge.
Sanofi is betting the partnership with Alphabet’s Verily Life Sciences LLC will spur advancements in the way diabetes is monitored and treated and help it navigate an increasingly competitive market.
The venture, Onduo, plans to combine devices, software and medicine, according to a statement yesterday from Sanofi and Verily, previously known as Google Life Sciences.
“The beauty of the joint venture in a way is that we don’t rely on the typical 10-year development cycle of a pharmaceutical asset,” Stefan Oelrich, senior vice president and head of the global diabetes franchise at Sanofi, said in an interview. “We start to innovate today.”
Sanofi expects increased competition in the diabetes market to remain as cheaper copies of biotech drugs known as biosimilars are rolled out. It plans to distinguish itself from rivals with programs like the Verily venture, unveiled last year, Oelrich said.
Sanofi is investing US$248 million in cash and Verily is committing an “equivalent” amount, he said.
“With more market entrants and as the space gets more crowded, it will be more difficult to maintain your stance from a contracting and commercial standpoint,” Oelrich said. “There’s increased competition on price. I think it’s here to stay.”
The drugmaker has been reshaping its diabetes portfolio after cutting its three-year sales forecast for the business last year because of a slump in demand for its best-selling medicine, Lantus.
Sanofi is relying on new treatments including its Toujeo insulin to help make up for the Lantus revenue shortfall.
The company plans to step up efforts to convince purchasers that its drugs are better than rivals’ treatments, Oelrich said.
Lantus last month was replaced on CVS Health Corp’s 2017 list of covered drugs by Eli Lilly & Co’s Basaglar, a cheaper version of the insulin that is scheduled to be sold in the US starting in December.
Given Sanofi’s reliance on Lantus, it will be hard for the company to escape near-term pressure as such biosimilars are introduced, according to a Sept. 7 report from Berenberg Bank analysts in London.
Sanofi is carrying out “the biggest real-world evidence” program ever for Toujeo to highlight to payers the differences between the treatments, Oelrich said.
“It’s our job to make sure that we have a convincing value story behind that because not all these products are the same,” he said.
The results of the program, which involve more than 4,500 patients in the US and Europe through three studies, will assess the efficacy of the once-a-day insulin, with results expected next year.
The Sanofi and Verily venture will focus on developing ways to improve medication management and habits for patients and will be led by Joshua Riff as chief executive officer. The company will take advantage of Verily’s experience in miniaturized electronics, analytics and consumer software, according to the statement.
POOR INTERNAL CONTROLS: Insurance Bureau Director-General Shih Chiung-hwa said the company is expected to get back on track while its chairman is suspended The Financial Supervisory Commission (FSC) yesterday fined Shin Kong Life Insurance Co (新光人壽) NT$27.6 million (US$939,415) for a reckless investment that endangered its solvency, and suspended its chairman Eugene Wu (吳東進) for poor supervision. The penalty is the second-highest in a single case after Nan Shan Life Insurance Co (南山人壽) was fined NT$30 million in September last year and its chairman Du Ying-tzyong (杜英宗) suspended for two years, the commission said. In three rounds of special and regular examinations conducted since last year, the commission found that Shin Kong Life had given too much power to an asset and liability management committee
HEAVY INVESTMENT: Moody’s affirmed the firm’s ‘Aa3’ rating with a ‘stable’ outlook due to its leading position in the industry and ability to match customer requirements Taiwan Semiconductor Manufacturing Co’s (TSMC, 台積電) revenue this year is expected to increase about 21 percent to NT$1.29 trillion (US$44.01 billion) from NT$1.07 trillion last year, driven by strong demand for advanced 5-nanometer and 7-nanometer chips mainly used in smartphones and high-performance computing devices, a Moody’s Investors Service report on Wednesday said. TSMC’s rate of revenue growth next year is to increase to 7.5 percent, the ratings agency said. The company, which supplies 5-nanometer chips for Apple Inc’s new iPad series, has introduced the advanced chips ahead of its competitors and gained a significant share of the market for the foundry industry’s
Sony Corp has cut its estimated Play Station 5 (PS5) production for this fiscal year by 4 million units, down to about 11 million, following production issues with its custom-designed system-on-chip (SOC) for the new console, people familiar with the matter said. The Tokyo-based electronics giant in July boosted orders with suppliers in anticipation of heightened demand for gaming in the holiday season and beyond, as people spend more time at home due to the COVID-19 pandemic. However, the company has come up against manufacturing issues, such as production yields as low as 50 percent for its SOC, which have cut into
O2O BICYCLE SHOW: The Taiwan Bicycle Show next year is to be online to offline, with forums, audio-visual conferences and livestreaming of the offline events Local bicycle makers expect demand to continue outpacing supply due to orders triggered by the COVID-19 pandemic, with some companies seeing orders back up through next year. “Next year is all full in terms of orders. Our lead time on components is one year,” Giant Manufacturing Co Ltd (巨大機械) chairwoman Bonnie Tu (杜綉珍) told a news conference in Taipei organized by the Taiwan External Trade Development Council (TAITRA) to announce next year’s Taipei Cycle Show. The pandemic has reduced bicycle supplies and increased demand around the world, Robert Wu (吳盈進), chairman of KMC (Kuei Meng) International Inc (桂盟國際), one of the world’s